Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma. Issue 27 (9th July 2021)

• Record Type: Journal Article
• Authors: Jeong, Joonho; Park, Jung Gu; Seo, Kwang Ill; Ahn, Ji Hyun; Park, Jae Chun; Yun, Byung Cheol; Lee, Sang Uk; Lee, Jin Wook; Yun, Jong Hyouk
• Editors: Găman., Mihnea-Alexandru
• Is Part Of: Medicine. Volume 100:Issue 27(2021)
• Page Start: e26584
• Publication Date: 2021-07-09
• Subjects: HCC -- microvascular invasion -- recurrence-free survival -- TACE; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000026584
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Supplemental Digital Content is available in the text Abstract : Abstract: The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single session of TACE at a single university hospital were retrospectively analyzed. Factors that might affect tumor necrosis were determined by evaluating the TACE approach and by analyzing computed tomography and TACE findings, pathologic reports, and laboratory findings. In univariate analysis, microvascular invasion (MVI), radiological capsule appearance on the computed tomography, chronic hepatitis B, diabetes mellitus and serum albumin, MVI were significantly associated with tumor necrosis by TACE ( P < .02). In multivariate analysis, MVI was the only statistically significant factor in TACE-induced tumor necrosis ( P = .001). In univariate and multivariate analysis, MVI was the strongest factor for recurrence-free survival rate within 2 years ( P = .008, P = .002). MVI could be a crucial factor in determining TACE as an initial treatment for hepatocellular carcinoma. MVI is also a strong indicator of recurrence within 2 years after curative hepatic resection.